Fundraising Fox

Hephaistos-Pharma

Orsay, FR · Founded 2018 · 19 employees on LinkedIn · 6 known investors

Find your way into Hephaistos-Pharma

68 people in our graph share verified history with the Hephaistos-Pharma team — schools, employers, funds. One of them is your warm intro.

Laurie Menoudunlockedknows Martine Caroff · together at CNRS (overlapped)
×7knows the team · via CNRS
knows the team · via Hephaistos-Pharma
×3knows the team · via National Research Council Canada / Conseil national de recherches Canada

HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.

BiotechMedical Devices

Founders & leadership

Hephaistos-Pharma was founded in 2018 by Martine Caroff.

MCMartine Caroff
Martine CaroffinScientific FounderMartine Caroff is founder and Chief Scientific Officer of Hephaistos-Pharma, a biopharmaceutical company developing immune-stimulating therapeutics for oncology. She previously held the position of Research Director at the French National Center for Scientific Research (CNRS) and has specialized expertise in lipopolysaccharide structure and function.
FCFrederic Caroff
Frederic CaroffinCEO
FBFrederique Brune
Frederique BruneinCDO
SBStephan Braun
Stephan BrauninCMO
JKJerome Kerzerho
Jerome KerzerhoinCSO
CLChristel Lonneux
Christel LonneuxinCFO and HR

Board

DSDavid Sourdive
David SourdiveinChairman of the BoardVenture Partner at Elaia

Investors · 6

xista science ventures✓ verifiedKlosterneuburg · $162K – $4.3M
Elaia✓ verifiedParis · $108K – $1.6M
Angels SantéParis
Femmes Business AngelsreportedParis

Also in the syndicate · 2

Fondation Fournier-MajoieNoshaq

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

🔥Hot Seed Deals: Hephaistos-Pharma, VoltR, Klineo & Edoniafrenchtechjournal.com · May 2024Hephaistos-Pharma Raises €10.3M in Fundingfinsmes.com · May 2024

Frequently asked questions

What does Hephaistos-Pharma do?
HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.
Who founded Hephaistos-Pharma?
Hephaistos-Pharma was founded by Martine Caroff in 2018.
Who are Hephaistos-Pharma's investors?
Hephaistos-Pharma's investors include xista science ventures, Elaia, Angels Santé, Femmes Business Angels.
Where is Hephaistos-Pharma headquartered?
Hephaistos-Pharma is headquartered in Orsay, FR.